Ann: Results of Meeting, page-8

With a likely phase 3 BTX1503 trial... along with a rosacea trial and a hopeful advancement of the antibiotic platform (who knows what that would be worth) - they'd be mad not to throw the additional 10% capacity in there. Phase 3 trials are not cheap.

In fact it would be negligent if they didn't allow for it.

Exploration of non dilutive funding options are always on the table and management know how much shareholders have hurt in the last 12 months. I remember being on a phone call with one share holder absolutely giving it Matt Calahan about funding from shareholders going forward. I'm sure he hasn't forgotten.

It's all coming to the inflection point now though - will antibiotic be the game changing we all hope for? I am quite optimistic.

With the connections we have with our US broker in Cowan.... along with the experience of the board Botanix is well positioned to really take their products to market and make something very special out of all of this.

It's all certainly worth a hell of a lot more than 100 million. The world is no doubt watching.